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Learning Objectives:  
Participants will be able to: 
• Describe the Process for creating an 
evidence-based Guideline such as the 
2014 HTN Guidelines and how it differs 
from a Consensus Guideline. 
• Establish goal BP’s for patients based 
on their age, race and presence of 
Diabetes or Kidney Disease 
• Select initial medications of choice for 
treating high blood pressure. 
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The Panel Process 
• Strictly evidence-based 
• Focus only on randomized controlled trials assessing 
important health outcomes (no use of intermediate/surrogate 
measures) 
• Every included study is rated for quality by two independent 
reviewers using standardized tools 
• Evidence statements graded for quality using prespecified 
criteria 
• Separate grading strength of recommendations 
• Independent methodology team to ensure objectivity of the 
review 
• Initial set of recommendations focused on 3 key questions 
NHLBI Systematic Review and Guideline 
Development Process 
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NHLBI Evidence Quality Grading and 
Recommendation Strength 
Evidence Quality 
 
• High  
 Well-designed and 
conducted RCTs 
• Moderate  
 RCTs with minor limitations 
 Well-conducted 
observational studies 
• Low 
 RCTs with major limitations 
 Observational studies with 
major limitations 
 
 
Recommendation Strength 
 
• A – Strong  
• B – Moderate  
• C – Weak  
• D – Against 
• E – Expert Opinion 
• N – No Recommendation  
 
The 3 Most Important Questions in managing 
patients with high blood pressure 
1. In adults with HTN, does initiating 
antihypertensive pharmacologic therapy 
at specific BP thresholds improve health 
outcomes?  
Or put another way: 
At what BP should medication be started? 
 
The 3 Most Important Questions in managing 
patients with high blood pressure 
2. In adults with HTN, does treatment 
with antihypertensive pharmacologic 
therapy to a specified BP goal lead to 
improvements in health outcomes?  
Or put another way: 
How low should you set the goal for BP 
targets? 
 
The 3 Most Important Questions in managing 
patients with high blood pressure 
3. In adults with HTN, do various 
antihypertensive drugs or drug classes 
differ in comparative benefits and 
harms on specific health outcomes?  
Or put another way:  
What are the best drugs to start 
treatment with to achieve goal BP? 
 
What is different about the New Guidelines? 
• Strict adherence to an evidence-
based process (Not consensus 
panel) 
• Limited scope- it does not answer all 
questions about the management of 
high blood pressure. 
• New BP Goals for treatment and 
different first-line medications 
We examined studies for both Thresholds 
for treatment and Goals for treatment 
• Although some trials had higher 
thresholds for eligibility than the goals 
tested, the panel elected to simplify 
treatment by making the same 
thresholds and goals for blood 
pressure treatment. 
New Goal Blood Pressures for Adults: 
Quick Summary 
• For age 60 years and older without 
diabetes or kidney disease,   strong 
evidence to support Goal BP < 
150/90 based on Grade A level 
evidence 
• For all others, we recommend  Goal 
BP < 140/90 based on expert opinion 
 
Initial Drug Treatment Recommendations for 
High Blood Pressure 
• Non-Black Population without CKD: 
Thiazide-type diuretic, CCB, ACEI or 
ARB 
 B Level Evidence 
• Black Population including those with 
DM: Thiazide-type diuretic or CCB 
 B Level Evidence for general Population and C 
Level Evidence for DM 
Initial Drug Treatment Recommendations for 
High Blood Pressure 
• CKD* Population (Black and non-
Black, DM or not DM): ACEI or ARB 
(but not both together in any 
circumstance) 
 B Level Evidence 
 
*CKD based on eGFR < 60 ml/min/1.73m2 
and age less than 70 years old. 
Initial 
Pharmacotherapy 
Selection 
Diuretic 
(Thiazide
-Type) 
 
CCB ACEI/ARB 
BLOOD PRESSURE 
GOALS 
> 60 YO: 
SBP <150mmHg 
DBP < 90mmHg 
<60 YO, DM, CKD: 
SBP < 140mmHg 
DBP < 90mmHg 
 
 
 
 
SPECIFIC 
RECOMMENDATIONS  
African Americans: 
Diuretic/CCB 
CKD: 
ACEI/ARB 
X Don’t use ACEI + ARB 
 Use evidence-based dosing (HCTZ!) 
 Only use Beta Blockers with compelling 
indication 
 
Drug Therapy Recommendations 


Case Study: 
• 76 yo black male in your clinic with HTN, CAD but no MI, 
and Stage 2 CKD w/o proteinuria (eGFR 68 mL/min/1.73 
m2) for follow-up. 
• Meds: ASA 81 mg, atorvastatin 20 mg, HCTZ 25 mg, 
lisinopril 40 mg & metoprolol succinate 25 mg all daily. 
• He reports good health w/o angina or dyspnea, denies 
adverse drug effects and denies orthostatic light-
headedness. Is active though does not exercise. 
• Exam: P= 67, BP = 108/62. BMI = 24 kg/m2 with normal 
findings otherwise. 
How would you proceed with further 
management of this gentleman?  
Questions? 
Addendum Slides 
“Guidelines We Can Trust” from IOM Report 
1. Transparent 
2. Manage COI 
3. Group Composition 
4. Guideline development – Systematic 
review intersection 
 
“Guidelines We Can Trust” from IOM Report 
5. Establish Evidence rating system and 
Strength of Recommendation system 
6. Clear articulation of Recommendations 
7. External Review 
8. Updating 
Inclusion/Exclusion Criteria 
• Randomized Controlled Trials 
 RCTs are subject to less bias and represent the gold 
standard for determining efficacy and effectiveness1  
• Search dates: 1966 to present 
• Minimum one-year follow-up period 
• Studies with sample sizes less than 100 
excluded 
 
    1 Institute of Medicine. 2011. Finding What Works In Health Care. 
Standards For Systematic Reviews. Washington, DC: The National 
Academies Press. 
 
 
 
Outcomes Required to Include a Randomized 
Controlled Trial 
• Overall mortality, CVD-related mortality, CKD-related 
mortality, myocardial infarction, heart failure, 
hospitalization for heart failure, stroke 
• Coronary revascularization (includes coronary artery 
bypass surgery, coronary angioplasty and coronary 
stent placement), peripheral revascularization 
(includes carotid, renal, and lower extremity 
revascularization) 
• End stage renal disease (i.e., kidney failure resulting 
in dialysis or transplant), doubling of creatinine, 
halving of eGFR  
 
 
 
Supplement to 2014 Evidence-based guideline for the management of high blood pressure in adults: report by the panel appointed 
to 
th  Ei hth J i t N ti l C itt  (JNC 8) 
Standardized 
Scoring Used 
by the 
Independent  
Methodology 
Team 
Articles Screened = 
1496 
   Good = 8 
Included = 44 
 
Total Abstracted = 
26 
 
Excluded = 1452 
(Did not meet 
prespecified 
inclusion 
criteria) 
 
Poor = 18 Fair = 18 
Question 1: Among adults with hypertension, does  
initiating antihypertensive pharmacological therapy at specific BP 
thresholds improve health outcomes? 
Articles Screened = 
1978 
   Good = 17 
Included = 92 
 
Total Abstracted = 
56 
 
Excluded = 
1886 
(Did not meet 
prespecified 
inclusion 
criteria) 
 
 
 
 
 
Poor = 36 Fair = 39 
Question 2: Among adults, does treatment with antihypertensive 
pharmacological therapy to a specified BP goal lead to improvements 
in health outcomes? 
Articles Screened = 
2662 
   Good = 15 
Included = 101 
 
Total Abstracted = 
66 
 
Excluded = 
2561 
(Did not meet 
prespecified 
inclusion 
criteria) 
 
 
Poor = 35 Fair = 51 
Question 3: In adults with hypertension, do various antihypertensive 
drugs or drug classes differ in comparative benefits and harms on 
specific health outcomes? 
Question 1:  Diastolic BP Goal Trials 
Several trials used DBP goal 
<90 mm Hg and demonstrated 
consistent reduction of CVD 
events, e.g., VA morbidity 
trial, HDFP, MRC trial, … 
Recommendation 1 
• In the general population ≥60 years of age, 
initiate pharmacologic treatment to lower BP at 
SBP ≥150 mm Hg or DBP ≥90 mm Hg and treat to 
a goal SBP <150 mm Hg and goal DBP <90 mm 
Hg. 
 Strong Recommendation – Grade A 
  Question 1:  Trials Considered: ANBP, 1980; EWPHE, 1985; HYVET, 
2008; SHEP, 1991; Syst-Eur, 1997; HDFP Cooperative, 1979; 
Hypertension Stroke Cooperative, 1974; MRC, 1985; VA Cooperative, 
1967; VA Cooperative,  1970  
 Question 2: Trials Considered DBP: HYVET, 2008; MRC, 1985; VA 
Cooperative, 1967; VA Cooperative,  1970 ; VA Cooperative,  1974; 
ANBP, 1980; HDFP Cooperative, 1979; Cardio-Sis, 2009; JATOS, 
2008; VALISH, 2010; Syst-Eur, 1997; SHEP 1991  
 
 
 
 
 
 
 
 
Recommendation 1 cont. 
• Corollary Recommendation: In the general 
population ≥60 years of age, if pharmacological 
treatment for high BP results in lower achieved 
SBPs (for example, <140 mm Hg) and treatment is 
not associated with adverse effects on health or 
quality of life, treatment does not need to be 
adjusted. 
 Expert Opinion – Grade E 
 
Recommendation 2 
• In the general population <60 years of 
age, initiate pharmacologic treatment to 
lower BP at DBP ≥90 mm Hg and treat to 
a goal DBP <90 mm Hg.  
 For ages 30-59 years,  
 Strong Recommendation – Grade A 
 For ages 18-29 years,  
 Expert Opinion – Grade E 
Recommendation 3 
• In the general population <60 years of 
age, initiate pharmacologic treatment to 
lower BP at SBP ≥140 mm Hg and treat to 
a goal SBP <140 mm Hg. 
 Expert Opinion – Grade E 
Recommendation 4 
• In the population ≥18 years of age with 
CKD, initiate pharmacologic treatment to 
lower BP at SBP ≥140 mm Hg or DBP ≥90 
mm Hg and treat to  goal SBP <140 mm 
Hg and goal DBP <90 mm Hg. 
 Expert Opinion – Grade E 
  Trials Considered: REIN-2, 2005; AASK, 2002; MDRD, 
1994 
 
 
Recommendation 5 
• In the population ≥18 years of age with 
diabetes, initiate pharmacologic 
treatment to lower BP at SBP ≥140 mm 
Hg or DBP ≥90 mm Hg and treat to a goal 
SBP <140 mm Hg and goal DBP <90 mm 
Hg.  
 (Expert Opinion – Grade E) 
• Trials Considered: ACCORD, 2010; SHEP, 1996; Syst-Eur, 1999; 
ABCD- HTN Cohort, 2000; ABCD- Normotensive Cohort, 2002; 
HOT, 1998; UKPDS, 1998;  
 
Why is it important not to recommend 
intensifying medications to reduce BP below the 
level proven in trials? 
 
• Lower thresholds/goals identify a much larger population 
as having “HTN” and presumably needing drug therapy. 
(e.g., reducing definition of HTN from 140/90 to 120/80 
mm Hg doubles those with “HTN”) 
• Millions classified as “HTN” based on higher BP goals 
require more drugs to achieve lower BP goals. 
• Treating to lower BP levels may be harmful  
(J-curve?). 
• If neither beneficial nor harmful, resources would be 
wasted and patient adherence may suffer.  
This 2014 HTN evidence-based guideline focuses on 
the panel’s 3 highest ranked questions related to HTN 
management 
1. In adults with HTN, does initiating antihypertensive 
pharmacologic therapy at specific BP thresholds 
improve health outcomes? 
2. In adults with HTN, does treatment with 
antihypertensive pharmacologic therapy to a 
specified BP goal lead to improvements in health 
outcomes? 
3. In adults with HTN, do various antihypertensive 
drugs or drug classes differ in comparative benefits 
and harms on specific health outcomes?  
Comparisons of Diuretics and ACE Inhibitors 
Legend:   Circle = Primary outcome; Triangle = Secondary outcome or not specified,   -  Color: Green = Statistically 
significant where the ACE inhibitor did better (p < 0.05), Red = Statistically significant  where the ACE inhibitor did 
worse,  Yellow = p ≥ 0.05 and ≤ 0.10 Clear = p > 0.10  
Study Criteria and 
Characteristics 
Mortality 
Outcomes 
CHD Outcomes Cerebro-
vascular 
Heart Failure 
Outcomes 
Composite 
Outcomes 
ANBP2, 2003 
 
Adults, ages 65 to 84, with 
absence of recent CV events 
ACE:  ACE Inhibitor: Enalapril 
recommended; dose not 
specified 
DIU:  Diuretic: HCTZ 
recommended; dose not 
specified 
N: 6,083 
  
Median 4.1 years  
Fair 
 
 
 
Death from any 
cause 
HR (95% CI) for 
ACE: 
0.90 (0.75, 1.09) 
p = 0.27 
 
 
 
Non-fatal MI 
HR (95% CI) for 
ACE: 
0.68 (0.47, 0.99) 
p =  0.05 
 
 
Non-fatal 
coronary event 
HR (95% CI) for 
ACE: 
0.92 (0.73, 1.16) 
p =  0.49 
 
 
MI 
HR (95%  CI) for 
ACE: 
0.68 (0.47, 0.98) 
p = 0.04 
HR (95% CI) for 
ACE: 
0.74 (0.49, 1.11) 
p =  0.14 
 
 
Non-fatal stroke 
HR (95% CI) for 
ACE: 
0.93 (0.70, 1.26) 
p =  0.65 
 
 
Stroke 
HR (95% CI) for 
ACE: 
1.02 (0.78, 1.33) 
p =  0.91 
 
 
 
Fatal stroke 
events 
HR (95% CI) for 
ACE: 
1.91 (1.04, 3.50) 
p = 0.04 
 
 
Non-fatal HF 
HR (95% CI) for 
ACE: 
0.85 (0.62, 1.17) 
p =  0.32 
 
 
HF 
HR (95% CI) for 
ACE: 
0.85 (0.62, 1.18) 
p =  0.33 
 
 
 
Fatal HF events 
HR (95% CI) for 
ACE: 
0.24 (0.03, 1.94) 
p =  0.18 
 
 
 
Non-fatal CV 
event 
HR (95% CI) for 
ACE: 
0.86 (0.74, 0.99) 
p =  0.03 
 
 
All CV events or 
death from any 
cause 
HR (95% CI) for 
ACE: 
0.89 (0.79, 1.00) 
p = 0.05 
 
 
Fatal CV events 
HR (95% CI) for 
ACE: 
0.99 (0.72, 1.35) 
p = 0.94 
 
 
Evidence Tables 
 Institute of Medicine. 2011. Finding What Works In Health Care. Standards For Systematic Review. Washington, DC: The National Academies 
Press. 
Drug Therapy RCTs Considered 
• ACEs: CAPPP, 1999; ANBP2, 2003; ALLHAT, 2002; JMIC-B, 2004; 
STOP Hypertension-2 , 1999;  
• ARBs: CASE-J, 2008; SCOPE, 2003; MOSES, 2005; LIFE, 2002; LIFE, 
2002; LIFE, 2003; Jikei Heart Study, 2007; VALUE, 2004; Kyoto Heart 
Study, 2009;  
• Beta Blockers: ASCOT-BPLA, 2005; ELSA, 2002; LIFE, 2002; LIFE, 
2003; MAPHY; IPPPSH, 1985; MRC, 1985; HAPPHY, 1987;  
• CCBs: ALLHAT, 2002; CASE-J, 2008; ASCOT-BPLA, 2005; VALUE, 
2004; NORDIL, 2000; STOP Hypertension-2, 1999; MIDAS, 1996; 
ELSA, 2002; SHELL, 2003; JMIC-B, 2004; INSIGHT, 2000; MOSES, 
2005; CONVINCE, 2003; VHAS, 1997;  
• Thiazide-like diuretics: MRC, 1985; ALLHAT, 2002; ALLHAT, 2003; 
SHELL, 2003; VHAS , 1997; INSIGHT, 2000; MIDAS, 1996; HAPPHY , 
1987; MAPHY, 1988; ANBP2, 2003;  
• Combination TX: ACCOMPLISH, 2008; ACCOMPLISH, 2010;  
Recommendation 6 
• In the general non-Black population, 
including those with diabetes, initial 
antihypertensive treatment should include 
a thiazide-type diuretic, CCB, ACEI or ARB. 
 Moderate Recommendation – Grade B 
Drug Considerations 
• Each of the 4 drug classes recommended by the panel 
yielded comparable effects on overall mortality and CV, 
cerebrovascular, and kidney outcomes, with one 
exception: HF.  
• Initial treatment with a thiazide-type diuretic was more 
effective than a CCB or ACEI, and an ACEI was more 
effective than a CCB in improving HF outcomes. 
• While the panel recognized that improved HF outcomes 
was an important finding that should be considered when 
selecting a drug for initial therapy for HTN, the panel did 
not conclude that it was compelling enough within the 
context of the overall body of evidence to preclude the 
use of the other drug classes for initial therapy. 
Recommendation 7 
• In the general Black population, including 
those with diabetes, initial antihypertensive 
treatment should include a thiazide-type 
diuretic or CCB. 
 For general Black population: Moderate Recommendation – 
Grade B 
 For Blacks with diabetes: Weak Recommendation – Grade 
C 
Recommendation 8 
• In the population ≥18 years of age with 
CKD and HTN, initial (or add-on) 
antihypertensive treatment should include 
an ACEI or ARB to improve kidney 
outcomes. This applies to all CKD patients 
with HTN regardless of race or diabetes 
status. 
 Moderate Recommendation – Grade B 
Recommendation 9 
• The main objective of HTN treatment is to attain 
and maintain goal BP.   
• If goal BP is not reached within a month of 
treatment, increase the dose of the initial drug or 
add a 2nd drug from one of the classes in 
Recommendation 6 (thiazide-type diuretic, CCB, 
ACEI or ARB). Continue to assess BP and adjust 
the treatment regimen until goal BP is reached.  
• If goal BP cannot be reached with 2 drugs, add 
and titrate a 3rd drug from the list provided. Do 
not use an ACEI and an ARB together in the 
same patient.  
Recommendation 9, cont. 
• If goal BP cannot be reached using the drugs in 
Recommendation 6 because of a contraindication 
or the need to use more than 3 drugs to reach 
goal BP, antihypertensive drugs from other 
classes can be used. 
• Referral to a hypertension specialist may be 
indicated for patients in whom goal BP cannot be 
attained using the above strategy or for the 
management of complicated patients where 
additional clinical consultation is needed. 
 Expert Opinion – Grade E 
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Hypertension:  A Moving Target 
JNC Classifications: Diastolic Blood Pressure 
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